PUBLICACIONES
FEHV
1.
Carreño V, Navarro A, Hernández-Guío C. Epidemiología de la
hepatitis B. Rev Esp Enf Ap Dig 1979; 56: 589-596.
2.
Carreño V, Navarro A, Hernández-Guío C. Hepatitis viral aguda en
nuestro medio. Rev
Soc And Pat Digest 1979; Tomo II: 207-214.
3.
Carreño V, Navarro A, Hernández-Guío C. Virus de la
hepatitis. Rev
Esp Enf Ap Dig 1979; 56: 475-484.
4.
Carreño V, Navarro A, Ortiz F, Hernández-Guío C. Virus de la
hepatitis B y personal hospitalario. Rev
Clin Esp 1980; 157: 179-182.
5.
Aquino MA, Carreño V,
Porres JC, Hernández-Guío C. Alteraciones hepáticas en los
drogadictos.
Gastroenterol Hepatol 1980; 4: 356-359.
6. García
Mas JL, Carreño V, Hernández-Guío
C. Valor de la GGTP en el estudio de las enfermedades
hepatobiliares; su
comparación con los parámetros bioquímicos habituales. Rev
Esp Enf Ap Dig 1981; 59: 597-602.
7.
Carreño V. Pronóstico, evolución y tratamiento de la
hemocromatosis. Gastrum 1981; 6: 80-90.
8.
Carreño V. Pronóstico, evolución y tratamiento de la
CBP. Gastrum
1981; 6: 42-51.
9.
Carreño V, Porres JC, Hernández‑Guío C, Marina Fiol C,
Alvarez C, Hernando L. The significance of hepatitis B infection to
nurses, paramedics and laboratory workers. Proc Eur Symp Hepatitis
B. 1981; 27‑38. Ed. S. Krugman and S.Sherlock, MSD Int.,
Rahway.
10.
Weller IVD, Carreño V,
Fowler MJF, Monjardino J, Maniken D, Thomas HC, Sherlock S. Acyclovir
inhibits hepatitis B virus replication in man. Lancet 1982; i: 273.
11.
Weller IVD, Fowler MJF, Monjardino J, Carreño
V, Thomas HC, Sherlock S. Inhibition of hepatitis B viral replication
by lymphoblasted interferon. Phil Trans R Soc Lond (Biol) 1982; 299 (1094):
128-130.
12.
Carreño V. Hepatitis viral aguda. Ed. Europharma.
1982; 5-15.
13.
Carreño V. Virus No‑A,No‑B de la hepatitis: progresos
realizados. Rev
Clin Esp 1982; 167: 139-141.
14.
Weller IVD, Carreño V,
Fowler MJF, Monjardino J, Makinen D, Varghese Z, Sweny P, Thomas HC, Sherlock
S. Acyclovir in hepatitis B antigen‑positive chronic liver
diseases:
inhibition of viral replication and transient renal impairment with iv bolus
administration. J Antimicrobial Chemother 1983; 11: 223-231.
15.
Montaño L, Carreño V,
Ortiz O. Replicación viral y cambios en la expresión de los antígenos
tisulares HBs y HBc en pacientes con hepatitis viral crónica tipo B. Rev Clin
Esp 1983; 169: 99-101.
16.
Carreño V, González R, Porres JC, Ortíz F, Martín F, Hernández‑Guio
C. Prevalencia de anti‑HAV en la población
española. Rev
Esp Enf Ap Dig 1983; 64: 187-190.
17.
Escuin F, Conesa J, Sanz A, Selgas R, Pérez M, Torres A, Ara JM, Gómez
P, Carreño V, Lardinois R, Sánchez-Sicilia
L. Vacunación contra hepatitis B en una unidad de
diálisis. Nefrología
1983; 3: 287-293.
18.
Carreño V, Montaño L, De Torres M. Tratamiento de la
hepatitis
crónica por virus B. Rev Clin Esp 1983; 171: 73-76.
19.
Mora I, Porres JC, Carreño V. Marcadores
serológicos del virus B de la hepatitis (VBH). Progresos realizados. Rev
Clin Esp 1984; 173: 9-14.
20.
Carreño V. Tratamiento de las hepatitis crónicas por virus
B. Gastroenterol. Hepatol 1984 (Editorial); 7: 45-47.
21.
Carreño V, Porres JC, Mora I, Hernández‑Guío C. Utilidad
de la determinación de actividad DNA polimerasa del virus B de la hepatitis
(VBH‑DNAp)
en portadores crónicos de AgHBs. Rev
Clin Esp 1984; 174: 75-77.
22.
Porres JC, Carreño V, Hernández‑Guío
C. Estudio prospectivo de hepatitis agudas por virus A, B y No‑A,
No‑B: diferencias epidemiológicas y clínicas. Rev
Clin Esp 1984; 174: 31-34.
23.
Bas C, Carreño V, Porres
JC, Mora I, Gutiez J, De Torres M, Hernández‑Guío C. Sobreinfección
con agente delta en portadores crónicos de AgHBs en España. Características
clínicas, epidemiológicas y virológicas. Rev
Clin Esp 1984; 175: 67-69.
24.
Carreño V, Porres JC, Gutiez J, Hernández‑Guío C.
Reactivación vírica en hepatitis crónica por virus B con bajo nivel de
replicación. Gastroenterol Hepatol 1984; 7: 461.
25.
Carreño V, Alvarez Chiva V, Porres JC, Hernández‑Guío C,
Hernando L. Patrón serológico de respuesta al virus B de la hepatitis
en el personal sanitario. Gastroenterol Hepatol 1984; 7: 57-60.
26.
Alvarez V, Carreño V,
Plaza JJ, Mora I, Hernando L. Infección por virus de hepatitis en el
transplante renal. Estudio prospectivo. Nefrología 1984; 4: 313-317.
27.
Quiroga JA, Gonzalez O, Carreño
V, Mora I, Porres JC, Gutiez J, Hernández‑Guío C. Radioimmunoassay
for detecting hepatitis B core antigen in serum from patients with chronic
hepatitis B infection. Clin
Chem 1985; 31: 831-834.
28.
Mora I, Porres JC, Carreño V. Receptores
frente a albúmina humana polimerizada (RAHP): nuevos aspectos de la
infección por el virus B de la hepatitis (VBH). Rev
Clin Esp 1985; 176: 1-4.
29.
Carreño V, Mora I, Escuin F, Sánchez Sicilia L, Alvarez V, Casado
S, Alcázar JM, Hernando L, Porres JC, Carrasco JL, Lardinois R. Vaccination
against hepatitis B in renal
dialysis units: short or normal vaccination schedule?. Clin
Nephrol 1985; 24: 215-220.
30.
Salata H, Cortés JM, Enriquez de Salamanca R, Oliva H, Castro A, Kusak
E, Carreño V, Hernández-Guío C.
Porphyria cutanea tarda and hepatocellular carcinoma. Frequency
of ocurrence and related factors. J
Hepatol 1985; 1: 477-487.
31.
Carreño V. Marcadores de replicación viral; su
significado.
Actualizaciones en Medicina Digestiva. Ed. Garsi 1986; 129-133.
32.
Mora I, Carreño V, Porres
JC, Gutiez J, Hernández‑Guío C. Relación entre la presencia de
receptores frente a albúmina humana polimerizada (RAHP) y el nivel de replicación
viral en la infección crónica por el virus B de la hepatitis (VBH). Rev
Clin Esp 1986; 178: 278-282.
33.
Bartolomé J, Castillo I, Carreño
V, Mora I, Gutiez J, Porres JC, Hernández‑Guío C. Determinación
del DNA del virus B de la hepatitis (VBH‑DNA) en portadores crónicos de
AgHBs: relación con otros marcadores de replicación viral. Rev
Clin Esp 1986; 178: 432-435.
34.
Mora I, Porres JC, Hernández‑Guío C, Gutiez J, Carreño
V. Hemagglutination and immunofluorescence studies on polymerized human
serum albumin binding activity in chronic hepatitis B virus infection. Hepatology
1986; 6: 14-19.
35.
Carreño V, Bartolomé J. Progresos en el conocimiento de
la hepatitis por virus B: aporte de la biología molecular. Rev
Clin Esp 1986; 178: 238-239.
36.
Mora I, Porres JC, Bartolomé J, Hernández-Guio C, Gutiez J, Carreño
V. Receptors for polymerized human serum albumin and other hepatitis B
virus markers during acute hepatitis B; predictive value of the outcome of the
disease. Hepato-Gastroenterol
1986; 33: 250-254.
37.
Quiroga JA, Carreño V,
Porres JC, Mora I, Gutiez J, Hernández-Guío C. Comparación entre la
determinación de antígeno del core del virus B de la hepatitis (AgHBc) y
actividad DNA polimerasa como marcadores de replicación vírica.
Gastroenterol Hepatol 1986; 9: 363-366.
38.
Carreño V, Gutiez J, Mora I, Porres JC, Hernández-Guío C.
Estudio de poblaciones linfocitarias en pacientes con
hepatitis por virus B: relación con otras etiologías. Rev
Esp Enf Ap Dig 1986; 70: 493-496.
39.
Mora I, Porres JC, Bartolomé J, Quiroga JA, Gutiez J, Hernández-Guío
C, Bas C, Carreño V. Changes of
hepatitis B virus (HBV) markers during prolonged recombinant interferon
alpha-2A treatment of chronic HBV infection. J Hepatol 1987; 4: 29-36.
40.
Mora I, Carreño V, Porres
JC, Gutiez J, Hernández-Guío C. Hepatitis B surface
antigen/IgM complexes:
relation to receptors for polymerized human serum albumin, hepatitis B virus
(HBV)
DNA polymerase activity and HBV markers. Acta
Virologica 1987; 31: 116-125.
41.
Hernández-Guío C, Carreño V,
Porres JC, Mora I. Hepatitis no-A, no-B. Rev
Clin Esp 1987; 180: 100-103.
42.
Quiroga JA, Bartolomé J, Porres JC, Mora I, Gutiez J, Hernández-Guío
C, Carreño V. Identification of
different degrees of hepatitis B virus (HBV) replicaction by serological
(HBV-DNAp,
HBcAg and HBV-DNA) and histological (HBcAg) methods. Liver
1987; 7: 169-175.
43.
Mora I, Porres JC, Carreño V.
Niveles mínimos de receptores para albúmnia humana polimerizada en la vacuna
antihepatitis B derivada de plasma. Rev
Clin Esp 1987; 181: 172.
44.
Quiroga JA, Bartolomé J, Carreño
V, Mora I, Porres JC, Gutiez J, Hernández-Guío C. Detección del
anticuerpo de clase IgM contra el antígeno del core del virus B de la
hepatitis en pacientes con infección crónica. Rev
Clin Esp 1987; 181: 351-354.
45.
Carreño
V,
Mora I. Combination of recombinant interferons alpha and gamma in treatment of
chronic hepatitis B. Lancet 1987; ii: 1086.
46.
Carreño V, Porres JC, Mora I, Gutiez J, Quiroga JA, Ramon y Cajal
S, Oliva H, Compernolle C, Bartolomé J. A controlled study of treatment with
recombinant interferon alpha in chronic hepatitis B virus infection: induction
and maintenance schedules. Antiviral Res 1987; 8: 125-137.
47.
Mora I, Porres JC, Carreño V.
Receptors for polymerized human serum albumin in plasma derived hepatitis B
vaccines. Vaccine
1987; 5: 279-282.
48.
La Banda F, Carreño V.
Tratamiento de la hepatitis crónica B. Gastroenterol Hepatol 1987; 10 (supl.1):
48-54.
49.
Inglada L, Porres JC, La Banda F, Mora I, Carreño
V. Anti-IFN-alpha titres during interferon
therapy. Lancet 1987; ii: 1521.
50.
Carreño V, Porres JC, Mora I, Bartolomé J, Bas C, Gutiez J, Cortés
J, Hernández-Guío C. Prolonged (6 months) treatment of chronic hepatitis B
virus infection with recombinant leukocyte A interferon. Liver 1987; 7:
325-332.
51.
Bas C, Bartolomé J, Mora I, La Banda F, Porres JC, Hernández-Guío C,
Carreño V. Prevalence of
HBV-DNA
among anti-HD positive patients. En: The hepatitis Delta virus and its
infection, M. Rizzetto, J.L. Gerin, R.H. Purcell eds., Alan R. Liss ed., New
York, NY. 1987; p 327-328.
52.
De Torres M, Bas C, Bartolomé J, Porres JC, Hernández-Guío C, Carreño
V. Liver membrane antibodies and delta
superinfection. En: The hepatitis
Delta virus and its infection, M. Rizzetto, J.L. Gerin, R.H. Purcell eds.,
Alan R. Liss ed., New York, NY. 1987; p 335.
53.
Carreño V, La Banda F, Quiroga JA, Bartolomé J, Mora I. Terapia
antiviral de la hepatitis crónica por virus B. En: Avances en Gastroenterología,
M. Díaz-Rubio ed., Arán Ediciones S.A., Madrid. 1987; p 287-298.
54.
De Torres M, Carreño V,
Bartolomé J, Porres JC, Bas C, Quiroga JA, Mora I. Liver membrane antibodies
in chronic delta hepatitis. Digestion 1987; 38: 171-177.
55.
Quiroga JA, Mora I, Carreño V,
Herrera MI, Porres JC, Gerlich WH. Inhibition
of albumin binding to hepatitis B virions by monoclonal antibody to the preS2
domain of the viral envelope. Digestion
1987; 38: 212-220.
56.
Bas C, Bartolomé J, La Banda F, Porres JC, Quiroga JA, Mora I, Hernández-Guío C, Carreño V.
Infección por virus D de la hepatitis en portadores crónicos del virus B de
la hepatitis: Relación con el sistema HBe. An
Med Intern 1987; 4: 583-586.
57.
La Banda F, Carreño V.
Tratamiento de las hepatitis crónicas producidas por el virus B, delta y
No-A, No-B. Bol Soc Gal Pato Digest 1987; 10: 15-30.
58.
Porres JC, Mora I, Gutiez J, Bartolomé J, Quiroga JA, Bas C,
Compernolle C, Ordi J, Chocarro A, Carreño
V. Antiviral effect of recombinant gamma interferon in chronic hepatitis B
virus infection: A pilot study. Hepato-Gastroenterol
1988; 35: 5-9.
59.
La Banda F, Ruiz-Moreno M, Carreño
V, Bartolomé J, Gutiez J, Ramón y Cajal S, Moreno A, Mora I, Porres JC. Recombinant
a2-interferon
treatment in children with chronic hepatitis B. Lancet 1988; i: 250.
60.
Bas C, Bartolomé J, La Banda F, Porres JC, Quiroga JA, Mora I, Carreño
V. Assessment of hepatitis B Virus DNA levels in chronic HBsAg carriers
with or without hepatitis delta virus superinfection. J Hepatol 1988; 6:
208-213.
61.
Ibarra MZ, Mora I, Quiroga JA, Bartolomé J, La Banda F, Porres JC, Carreño
V. IgG and IgM auto-antiidiotype antibodies against antibody to HBsAg in
chronic hepatitis B. Hepatology 1988; 8: 775-780.
62.
Bartolomé J, Castillo I, Mora I, Gutiez J, Porres JC, Carreño
V. Different levels of hepatitis B virus replication among hepatitis B e
antigen positive chronic carriers. Acta
Virol 1988; 32: 193-197.
63.
Bartolomé J, Castillo I, Bas C, Mora I, Porres JC, Carreño
V. Detección del DNA del virus B de la hepatitis en biopsias hepáticas
de portadores crónicos de AgHBs. Rev
Clin Esp 1988; 183: 67-70.
64.
Gómez C, La Banda F, Porres JC, Mora I, Andrés A, Bartolomé J,
Quiroga JA, Gutiez J, Castillo I, Bas C, Armenteros E, Ibarra MZ, Carreño
V. Combined recombinant alpha and gamma interferon treatment of chronic
hepatitis B virus infection. En: Viral Hepatitis and Liver Diseases, Alan R.
Liss ed., New York, NY. 1988; 872-874.
65.
Quiroga JA, Mora I, Porres JC, Carreño
V. Elevation of 2',5'-Oligoadenylate synthetase activity and
HLA-I
associated ß2-microglobulin in response to recombinant interferon gamma
administration in chronic HBeAg positive hepatitis. J
Interferon Res 1988; 8: 755-763.
66.
Porres JC, Carreño V, Mora
I, Gutiez J, Moreno A, Ramón y Cajal S, Marrón JA, Bartolomé J. Different
doses of recombinant interferon alpha in the treatment of chronic hepatitis B
patients without antibodies against the human immunodeficiency virus. Hepato-Gastroenterol
1988; 35: 300-303.
67.
Carreño V, Quiroga JA, Bartolomé J. Hepatitis: problemas
pendientes. Bol Fund Jiménez Díaz 1988; 12: 36-37.
68.
Carreño V, Castillo I, Mora I. Actualidad en el estudio de los
marcadores del virus del SIDA. Bol Fund Jiménez Díaz. 1988; 12: 105-107.
69.
Ruiz-Moreno M, García-Aguado J, Carreño
V, Alvarez Sala L, Rincón P, López-Linares M, Bas C. Prevalencia de
hepatitis por virus A, B y D en niños. An Esp Pediatr 1988; 29: 357-362.
70.
Castillo I, Carreño V,
Bartolomé J, Porres JC, Mora I, Herrera MI. Virus-like
particles associated with reverse transcriptase activity in acute sporadic
Non-A, Non-B hepatitis. Digestion 1989; 42: 7-15.
71.
Porres JC, Carreño V,
Bartolomé J, Gutiez J, Castillo I. A dynamic study of the intrafamilial
spread of hepatitis B virus infection: relation with the viral replication. J
Med Virol 1989; 28: 237-242.
72.
Ruiz-Moreno M, Camps T, García J, Porres JC, Oliva H, Bartolomé J, Carreño
V. Serological and histological follow-up of chronic hepatitis B
infection.
Arch Dis Child 1989; 64: 1165-1169.
73.
Porres JC, Carreño V,
Ruiz-Moreno M, Marrón JA, Bartolomé J. Interferon antibodies in patients
with chronic HBV infection treated with recombinant interferon. J Hepatol
1989; 8: 351-357.
74.
Ibarra MZ, Mora I, Bartolomé J, Porres JC, Carreño
V. Detection of proteins encoded by the pre-S region of hepatitis B virus
in the sera of HBsAg carriers: relation to viral replication. Liver
1989; 9: 153-158.
75.
Porres JC, Carreño V,
Bartolomé J, Moreno A, Galiana F, Quiroga JA. Treatment
of chronic delta infection with recombinant human interferon alpha 2c at high
doses. J Hepatol 1989; 9: 338-344.
76.
Saldanha J, di Blas F, Bas C, Velosa J, Ramalho FM, di Marco V, Mora I,
Carreiro de Moura M, Carreño V,
Craxi A, Thomas HC, Monjardino J. Detection of hepatitis delta virus RNA in
chronic liver disease. J Hepatol 1989; 9: 23-28.
77.
Moraleda G, Bartolomé J, Madejón A, Martinez MG, Moreno E, Loinaz C,
Gómez M, Carreño V.
Influence of the positivity to HBV-DNA in serum, liver and peripheral
mononuclear cells in the risk of HBV allograft infection after liver
transplantation in HBsAg-positive recipients. Traspl Organs Tiss. 1989; 1:
19-22.
78.
Moreno A, Ramón y Cajal S, Marazuela M, Carreño
V, Milicua JM, Cerezo E, Cuesta C, Oliva H. Sanded nuclei in delta
hepatitis. Liver
1989; 9: 367-371.
79.
Quiroga JA, Carreño V.
Interferon and hepatitis B vaccine in haemodialysis patients. Lancet 1989; i:
1264.
80.
Ruiz-Moreno M, Jimenez J, Porres JC, Bartolomé J, Moreno A, Carreño
V. A controlled trial of recombinant interferon alpha in caucasian
children with chronic hepatitis B. Digestion 1990; 45: 26-33.
81.
Bartolomé J, Moraleda G, Castillo I, Martínez MG, Porres JC, Carreño
V. Presence of HBV-DNA in peripheral blood mononuclear cells from
anti-HIV
symtomless carriers. J Hepatol 1990; 10: 186-190.
82.
Castillo I, Bartolomé J, Quiroga JA, Porres JC, Carreño
V. Detection of HBeAg/anti-HBe immune complexes in the reactivation of
hepatitis B virus replication among anti-HBe chronic carriers. Liver 1990; 10:
79-84.
83.
Ibarra MZ, Porres JC, Bartolomé J, Escudero M, Quiroga JA, Carreño
V. Changes in anti-idiotype antibodies against
anti-HBs during recombinant
interferon treatment of chronic hepatitis B. J Interferon Res 1990; 10:
367-373.
84.
Porres JC, Hernández-Guío C, Carreño
V. Avances realizados en el tratamiento de la hepatitis crónica por virus
C. Rev Esp Enf Digest 1990; 77: 437-438.
85.
Quiroga JA, Castillo I, Porres JC, Casado S, Sáez-Royuela F, Martínez
MG, Gómez M, Inglada L, Sánchez-Sicilia
L, Mora I, Galiana F, Barril G, Carreño
V. Recombinant gamma interferon as adjuvant to hepatitis B vaccine in
hemodialysis patients. Hepatology 1990; 12: 661-663.
86.
Carreño V, Mora I, Quiroga JA, Bartolomé J, Bas C, Castillo I.
Aspectos celulares y moleculares de la hepatitis vírica. En: Nuevas
tendencias en Hepatología, M Cascales Ed., Madrid, CSIC. 1990.
87.
Bartolomé J, Moraleda G, Molina J, Domínguez F, Porres JC, Carreño
V. Hepatitis B virus DNA in liver and peripheral blood mononuclear cells
during reduction in virus replication. Gastroenterology 1990; 99: 1745-1750.
88.
Bartolomé J, Moraleda G, Ruíz-Moreno M, Porres JC, Carreño
V. Hepatitis B virus DNA patterns in the liver of children with chronic
hepatitis B. J Med Virol 1990; 31: 195-199.
89.
Gómez Rubio M, Porres JC, Castillo I, Quiroga JA, Moreno A, Carreño
V. Prolonged treatment (18 months) of chronic hepatitis C with recombinant
a-interferon
in comparison with a control group.
J Hepatol 1990; 11 (S1): s63-s67.
90.
Carreño V, Quiroga JA. Vacunas frente al virus de la hepatitis
B.
Problemas pendientes. Rev.
Clin. Esp. 1990; 187: 247-248.
91.
Moraleda G, Bartolomé J, Martínez MG, Porres JC, Carreño
V. Influence of hepatitis delta virus replication in the presence of
hepatitis B virus DNA in peripheral blood mononuclear cells. Hepatology 1990;
12: 1290-1294.
92.
Madejón A, Castillo I, Bartolomé J, Melero M, Campillo ML, Porres JC,
Moreno A, Carreño V. Detection of
HDV-RNA by PCR in serum of patients with chronic HDV infection. J Hepatol
1990; 11: 381-384.
93.
Carreño V, Saez-Royuela F, Gómez Rubio M. Use of recombinant
interferon in the treatment of chronic non-A, non-B hepatitis: Results of two
controlled trials. Proceedings of the IV International Symposium on Viral
Hepatitis. Mediscript Ed. London (UK). (1990);
103-106.
94.
Carreño V, Quiroga JA. Epidemiología y prevención de la
hepatitis vírica en pacientes hemodializados. Gastroenterol
Hepatol 1990; 13: 517-518.
95.
Martínez MG, Castillo I, Quiroga JA, Porres JC, Carreño
V. Detection of serum inhibitory factor for lymphocyte stimulation in
chronic viral hepatitis: relationship with the replication level. Liver
1991; 11: 48-52.
96.
Ruiz-Moreno M, Rúa MJ, Carreño
V, Quiroga JA, Manns M, Meyer zum Büschenfelde KH. Autoimmune
chronic hepatitis type 2 manifested during interferon therapy in children. J
Hepatol 1991; 12: 265-266.
97.
Saez-Royuela F, Porres JC, Moreno A, Castillo I, Martinez G, Galiana F,
Carreño V. High doses of
recombinant alpha interferon or gamma interferon for chronic hepatitis C: a
randomized controlled trial. Hepatology 1991; 13: 327-331.
98.
Castillo I, Bartolomé J, Madejón A, Melero M, Porres JC, Carreño
V. Hepatitis delta virus RNA detection in chronic HBsAg carriers with and
without HIV infection. Digestion 1991; 48: 149-156.
99.
Ruiz-Moreno M, Rua MJ, Molina J, Moraleda G, Moreno A, García-Aguado
J, Carreño V. Prospective
randomized controlled trial of alpha interferon in children with chronic
hepatitis B. Hepatology 1991; 13: 1035-1039.
100.
Carreño V, Quiroga JA. Treatment
of chronic hepatitis B with alpha interferon: Present and future. J Hepatol
1991; 13: S2.
101.
Quiroga JA, Campillo ML, Castillo I, Bartolomé J, Porres JC, Carreño
V. IgM antibody to hepatitis C virus in acute and chronic hepatitis
C.
Hepatology 1991; 14: 38-43.
102.
Diez A, Quiroga JA, Melero M, Moraleda G, Castillo I, Porres JC, Carreño
V. Detection of antibody to calmodulin in chronic
viral hepatitis: lack
of correlation with virus replication and hepatocellular damage. Digestion
1991; 49: 125-133.
103.
Carreño V, Porres JC, Ruiz-Moreno M, Gutiez J, Bartolomé J.
Estudio controlado de tratamiento con interferon alfa recombinante en la
hepatitis crónica por virus B en la infancia. Rev
Esp Enf Digest 1991; 79: 24-28.
104.
Escudero MM, Quiroga JA, Bartolomé J, Carreño
V. Analysis of serum pre-S antigens in chronic hepatitis B virus infection
in relation to the expression pattern of hepatitis B virus DNA in the liver.
Digestion 1991; 49: 204-211.
105.
Moraleda G, Bartolomé J, Molina J, Castillo I, Carreño
V. Analysis of hepatitis B virus DNA, liver disease and influence of
antibody to hepatitis C virus in anti-HBe chronic carriers. Liver
1991; 11: 352-357.
106.
Porres JC, Carreño V,
Moreno A, Bartolomé J. Reactivación del virus B de la hepatitis en
portadores crónicos con anti-HBe. Rev
Clin Esp 1991; 189: 68-72.
107.
Thomas HC, Dusheiko GM, Lok ASF, Farrell GC, Williams SJ, Cooksley WGE,
Pérez V, Tanno H, Carreño V,
Ryff JC. Comparative study of three doses of interferon alpha-2A in chronic
active hepatitis B. En: Viral Hepatitis and Liver Disease. F.B. Hollinger,
S.M. Lemon, H. Margolis, eds. Williams and Wilkins, Baltimore, MD, 1991: 641-642.
108.
Campillo ML, Quiroga JA, Bartolomé J, Moraleda G, Castillo I, Carreño
V. Protein composition of hepatitis B virus e antigen in the natural
course of the disease and following interferon therapy. J Clin Microbiol 1992;
30: 1256-1261.
109.
Carreño V, Tapia L, Ryff JC, Quiroga JA, Castillo I. Treatment of
chronic hepatitis C by continuous subcutaneous infusion of interferon-alpha. J
Med Virol 1992; 37: 215-219.
110.
Ortiz A, Quiroga JA, García Delgado R, Carreño
V, Caramelo C. Virus de la hepatitis C y
crioglobulinemia. Rev Clín Esp
1992; 190: 157.
111.
Ruiz-Moreno M, Rúa MJ, Castillo I, García-Novo MD, Santos M, Navas S,
Carreño V. Treatment of children
with chronic hepatitis C with recombinant alpha interferon: a pilot study.
Hepatology 1992; 16: 882-885.
112.
Castillo I, Bartolomé J, Quiroga JA, Carreño
V. Comparison of several PCR procedures for detection of HCV RNA using
different regions of the HCV genome. J Virol Methods 1992; 38: 71-80.
113.
Caramelo C, Carreño V,
González-Parra E, Quiroga JA, Garrón MP, Marriott E, Ortíz A, Galera A, López
MD, Porres JC. Positive
ELISA-2 is pathologically relevant in ELISA-1-negative patients on
hemodialysis. Nephron 1992; 61: 474.
114.
Marriott E, Quiroga JA, Carreño
V. Re-Treatment of chronic hepatitis C with
alpha-interferon. J Infect Dis
1992; 166: 1200-1.
115.
Ruíz-Moreno M, Carreño V,
Rúa MJ, Cotonat T, Serrano B, Santos M,
Marriott E. Increase in triglicerides during alpha interferon treatment
of chronic viral hepatitis. J Hepatol 1992; 16: 384.
116.
Carreño V, Castillo I, Molina J, Porres JC, Bartolomé J. Long-term
follow-up of hepatitis B chronic carriers who responded to interferon therapy.
J Hepatol 1992; 15: 102-106.
117.
Quiroga JA, Bosch O, Gonzalez R, Marriott E, Castillo I, Bartolomé J, Carreño
V. Immunoglobulin M antibody to hepatitis C virus during interferon
therapy for chronic hepatitis C. Gastroenterology 1992; 103: 1285-1289.
118.
Ruiz-Moreno M, Rúa MJ, Moraleda G, Guardia L, Moreno A, Carreño
V. Treatment with interferon gamma versus interferons alfa and gamma in
children with chronic hepatitis B. Pediatrics 1992; 90: 254-258.
119.
Molina J, Bartolomé J, Moraleda G, Ruiz-Moreno M, Rúa MJ, Moreno A, Carreño
V. Persistence of hepatitis B virus DNA after eduction of viral
replication in serum and liver. J Med Virol 1992; 38: 11-15.
120.
Bosch O, Tapia L, Quiroga JA, Carreño
V. An escalating dose regime of recombinant
interpheron-alpha 2A in the
treatment of chronic hepatitis C. J Hepatol 1993; 17: 146-149.
121.
Bartolomé J, Castillo I, Quiroga JA, Navas S, Carreño
V. Detection of hepatitis C virus RNA in serum and peripheral blood
mononuclear cells. J Hepatol 1993; 17: s90-s93.
122.
Moreno A, Martinez CJ, Carreño
V. Liver biopsy and the etiologic diagnosis of chronic hepatitis. J
Hepatol 1993; 17: s112-s115.
123.
Moreno-González E, Loinaz C, García I, Lumbreras C, Gómez R,
Moraleda G, Pinto IG, Colina F, Jiménez C, Carreño
V, Bercedo J, Ibañez J, Alberti N, Maffettone
V. Liver transplantation in chronic viral B and C hepatitis.
124.
Carreño V, Marriott E, Quiroga JA. Other
approaches to the treatment of chronic viral hepatitis. J Hepatol 1993; 17:
s127-s129.
125.
Madejón A, Castillo I, Cotonat T, Carreño
V. Significance of low HDV replication levels during the natural history
of HDV infection. J Hepatol 1993; 17: s157-s160.
126.
Navas S, Castillo I, Carreño V.
Detection of plus and minus HCV-RNA in normal liver of anti-HCV positive
patients. Lancet
1993; 341: 904-905.
127.
Carreño V. Ultimos avances en hepatología. Hepatol
Clin 1993; 1: 71-82.
128.
Carreño V, Moreno A, Galiana F, Bartolomé J. Alpha and gamma
interferon versus alpha interferon alone in chronic hepatitis B. A randomized
controlled trial. J Hepatol 1993; 17: 321-325.
129.
Marriott E, Navas S, del Romero J, García S, Castillo I, Quiroga JA, Carreño
V. Treatment with recombinant
alpha-interferon of chronic hepatitis C in anti-HIV positive patients. J Med Virol 1993; 40: 107-111.
130.
Carreño V. Ultimos avances en hepatología. Hepatol ClIn 1993;
1:
149-162.
131.
Ruiz-Moreno M, García R, Rúa MJ, Serrano B, Moraleda G, Feijoo E,
Bartolomé J, Ortiz F, Castillo I, Carreño
V. Levamisole and interferon in children with chronic hepatitis
B.
Hepatology 1993; 18: 264-269.
132. Carreño V, Quiroga JA. Ultimos avances en hepatología. Hepatol Clin 1993; 1: 224-244.
133.
Bosch O, Moraleda G, Castillo I, Carreño
V. Treatment of chronic hepatitis B with recombinant interferon alpha
versus recombinant interferon alpha plus levamisole. J Hepatol 1993; 19:
437-441.
134.
Martín J, Bosch O, Moraleda G, Bartolomé J, Quiroga JA, Carreño
V. Pilot study of recombinant human
granulocyte-macrophage colony-stimulating
factor in the treatment of chronic hepatitis B. Hepatology 1993; 18: 775-780.
135.
Caramelo C, Ortiz A, Aguilera B, Porres JC, Navas S, Marriott E,
Alberola ML, Alamo C, Galera A, Garron MP, González-Parra E, Fernández de
Gabriel MV, Oliva H, Carreño V.
Liver disease patterns in hemodialysis patients with antibodies to hepatitis C
virus. Am
J Kidney Dis 1993; 22: 822-828.
136.
Carreño V. Virus C de la hepatitis: vacunación y tratamiento
problemáticos. Rev
Clin Esp 1993; 192: 155-156.
137.
Carreño V, Hernández-Guío C, Bartolomé J, Quiroga JA. Cambios
en los niveles séricos de la actividad 2',5'-oligoadenilato sintetasa,
ß2-microglobulina
y neopterina durante el aclaramiento del virus B de la hepatitis con o sin
agudización en las transaminasas. Rev
Esp Enf Digest 1993; 83: 169-175.
138.
Carreño V, Bartolomé J, Castillo I. Ultimos avances en hepatología.
Hepatol Clin 1993; 1: 335-354.
139.
Alberola ML, Caramelo C, Navas S, Garrón MP, Aguilera B, Carreño
V, Bermejillo T, Reyero R, Galera A, Marriott E, Ortiz A, Alcázar R,
Alamo C, Porres JC. Infección
por virus C de la hepatitis en pacientes en hemodiálisis y en receptores de
transplante renal. Hepatol Clin 1993; 1: 185-193.
140.
Ortiz A, Quiroga JA, García Delgado R, Carreño
V, Caramelo C. Virus de la hepatitis C y
crioglobulinemia. Rev Clín Esp
1993; 192: 157.
141.
Carreño V, Bartolomé J, Castillo I. Long-term effect of
interferon therapy in chronic hepatitis B. J Hepatol 1994; 20: 431-435.
142.
Carreño V, Pardo M. Tratamiento de la hepatitis crónica por VBH y
VDH. Rev.
And Patol Digest 1994; 17: 17-21.
143.
Caramelo C, Navas S, Alberola ML, Bermejillo T, Reyero A, Carreño
V. Evidence against transmission of hepatitis C virus through hemodialysis
ultrafiltrate and peritoneal fluid. Nephron
1994; 66: 470-473.
144.
Carreño V. Ultimos avances en hepatología. Hepatol
Clin 1994; 2: 47-74.
145.
Madejón A, Cotonat T, Bartolomé J, Castillo I, Carreño
V. Treatment of chronic hepatitis D virus infection with low and high
doses of interferon-alpha 2a: Utility of polymerase chain reaction in
monitoring antiviral response. Hepatology 1994; 19: 1331-1336.
146.
Castillo I, Bartolomé J, Navas S, Gonzalez S, Herrero M, Carreño
V. Virological and biochemical long-term
follow-up of patients with
chronic hepatitis C treated with interferon. Hepatology 1994; 19: 1342-1346.
147.
Pardo M, Cotonat T, Herrero M, Marriott E, Artillo S, Quiroga JA, Carreño
V. Retreatment of chronic hepatitis C virus
infection. Lancet 1994; 343:
1568-1569.
148.
Navas S, Castillo I, Bartolomé J, Marriott E, Herrero M, Carreño
V. Positive and negative hepatitis C virus RNA strands in
serum, liver and
peripheral blood mononuclear cells in anti-HCV patients: Relation with the
liver lesion. J Hepatol 1994; 21: 182-186.
149.
Pardo, Carreño V. Lack of
efficacy of inosine pranobex in the treatment of chronic hepatitis C. J
Hepatol 1994; 21: 278.
150.
López-Alcorocho JM, Moraleda G, Bartolomé J, Castillo I, Cotonat T,
Aguilar J, Ortega E, Pons JA, Salmerón J, Vázquez-Iglesias JL, Carreño
V. Analysis of hepatitis B precore region in serum and liver of chronic
hepatitis B virus carriers. J Hepatol 1994; 21: 353-360.
151.
Quiroga JA, Herrero M, Castillo I, Navas S, Pardo M, Carreño
V. Long-term follow-up study of serum IgM antibody to hepatitis C virus
(HCV),
HCV replication and liver disease outcome in chronic hepatitis C. J Infect Dis
1994; 170: 669-673.
152.
Carreño V, Quiroga JA. Hepatitis viral
aguda. En: Tratado de
Medicina Interna, Sección XI, Capítulo 5. M. Díaz Rubio, D. Espinós Eds.
Editorial Panamericana, Madrid, 1994; 1384-1396
153.
Krogsgaards K, Bindslev N, Christensen E, Craxi A, Schlichting P,
Schalm S, Carreño
V, Trepo C, Gerken G, Thomas HC, Andersen PK, Ring-Larsen H and the
European Concerted Action on Viral Hepatitis (Eurohep). The treatment effect
of alpha interferon in chronic hepatitis B is independent of pre-treatment
variables. Results based on individual patient data from 10 clinical
controlled trials. J
Hepatol 1994; 21: 646-655.
154.
Carreño V, Bartolomé J, Castillo I. Ultimos avances en hepatología.
Hepatol
Clin 1994; 2: 131-160.
155.
Quiroga JA, Martín J, Pernas M, Pardo M, Herrero M, Castillo I,
Bartolomé J, Carreño V. Evidence
of Subtype-Specific Antibodies to Antigenic Epitopes in the NS5 Region of
Hepatitis C Virus in the Circulation of Patients with Chronic Hepatitis C.
Clin Diag Lab Immunol 1994; 1: 545-551.
156.
González Parra E, Bermejillo T, Martín J, Aguilera B, Ortiz A, Fernández
de Gabriel MV, Carreño V,
Caramelo C. Niveles de interferón recombinante humano alfa 2b en pacientes en
hemodiálisis. Nefrología
1994; 14: 207-210
157.
Martín J, Quiroga JA, Bosch O, Carreño
V. Changes in cytokine production during therapy with
granulocyte-macrophage colony-stimulating factor in patients with chronic hepatitis B. Hepatology
1994; 20: 1156-1161.
158.
Carreño V. Ultimos avances en hepatología. Hepatol
Clin 1994; 2: 201-228.
159.
Quiroga JA, Martín J, Pardo M, Carreño
V. Serum levels of soluble immune factors and pathogenesis of chronic
hepatitis C, and their relation to therapeutic response to alpha-interferon.
Dig Dis Sci 1994; 39: 2485-2496.
160.
Carreño V, Bartolomé J, Madejón A. Hepatitis delta virus
infection: Molecular biology and treatment. Dig Dis 1994; 12: 265-275.
161.
Carreño V, Castillo I, Quiroga JA. Ultimos avances en hepatología.
Hepatol
Clin 1994; 2: 275-308.
162.
Thomas HC, Lok ASF, Carreño V,
Farrell G, Tanno H, Pérez V, Dusheiko GM, Cooksley G, Ryff JC and the
International Hepatitis Trial Group. Comparative study of three doses of
interferon-alpha 2a in chronic active hepatitis B. J Viral Hepatitis 1994; 1:
139-148.
163.
Pernas M, Bartolomé J, Castillo I, Quiroga JA, Pardo M, Carreño
V. Sequence of non-structural regions 3 and 5 of hepatitis C virus genomes
from Spanish patients: existence of a predominant variant related to type 1b. J
Gen Virol 1995; 76: 415-420.
164.
Navas S, Bosch O, Castillo I, Marriott E, Carreño
V. Porphyria cutanea tarda and hepatitis C and B viruses
infection: A
retrospective study. Hepatology
1995; 21: 279-284.
165.
González S, Navas S, Madejón A, Bartolomé J, Castillo I, Moraleda G,
Martín J, Marriott E, Herrero M, Carreño
V. Hepatitis B and D genomes in hepatitis B surface antigen negative
patients with chronic hepatitis C. J Med Virol 1995; 45: 168-173.
166.
Bartolomé J, Madejón A, Carreño
V. Ribozymes: structure, characteristics and use as potential antiviral
agents. J Hepatol 1995; 22: s57-s64.
167.
Navas S, Carreño V.
Semiquantification by AmplicorTM assay of hepatitis C virus genome
during therapy. J Hepatol 1995; 22: s115-s117.
168.
Carreño V, Quiroga JA. Biologic
response modifiers in chronic hepatitis C. J Hepatol 1995; 22: s122-s126.
169.
Carreño V, Quiroga JA, Castillo I. Ultimos avances en hepatología.
Hepatol
Clin. 1995; 3: 39-66.
170.
Pardo M, Castillo I, Navas S, Carreño
V. Treatment of chronic hepatitis C with cirrhosis with recombinant human
granulocyte colony-stimulating factor plus recombinant interferon alpha. J Med
Virol 1995; 45: 439-444.
171.
Ruíz-Moreno M, Camps T, Jiménez J, López R, Castillo I, Bartolomé
J, Carreño V. Factors predictive
of response to interferon therapy in children with chronic hepatitis B. J
Hepatol 1995; 22: 540-544.
172.
Carreño V. Castillo I. Ultimos avances en hepatología. Hepatol
Clin 1995; 3: 91-118.
173.
Castillo I, Bartolomé J, Ruiz-Moreno M, Sánchez V, Navas S, Carreño
V. Hepatitis C virus genotypes in serum and liver of children with chronic
hepatitis C. Pediatric Res 1995; 38: 618-620.
174.
Pardo M, Marriott E, Moliner MC, Quiroga JA, Carreño
V. Risk and benefits of interferon-alpha in the treatment of
hepatitis.
Drug Safety 1995; 13: 304-316.
175.
Quiroga JA, van Binsbergen J, Wang CY, Pardo M, Navas S, Trines Ch,
Herrero M, Carreño V.
Immunoglobulin M antibody to hepatitis C virus core antigen: Correlations with
viral replication, histological activity and liver disease outcome. Hepatology
1995; 22: 1635-1640.
176.
Carreño V, Bartolomé J, Castillo I. Ultimos avances en hepatología.
Hepatol
Clin 1995; 3: 223-240.
177.
López-Alcorocho JM, Cabrerizo M, Bartolomé J, Cotonat T, Carreño
V. Analysis of hepatitis B virus precore variants in hepatitis B e
antibody-positive patients treated with prednisone plus interferon. J Viral
Hepatitis 1995; 2: 279-284.
178.
Quiroga JA, Pardo M, Navas S, Martín J, Carreño
V. Patterns of immune responses to the
host-encoded GOR and hepatitis C
virus core-derived epitopes with relation to hepatitis C viremia, genotypes
and liver disease severity. J Infect Dis 1996; 173: 300-305.
179.
Martín J, Navas S, Quiroga JA, Carreño
V. Recombinant human granulocyte
colony-stimulating factor reduces
hepatitis C virus replication in mononuclear cells from chronic hepatitis C
patients. Cytokine
1996; 8: 313-317.